About Index Trending news
Analyze
Pricing
Alimera Sciences

Alimera Sciences

Alimera Sciences

Biopharmaceutical company that researches, develops and commercializes prescription ophthalmic pharmaceuticals with a focus on the back of the eye, or retina.

Elsewhere

Alexa global traffic share

Twitter followers

Latest funding
Post-IPO equity
$26,500,000
Post-IPO debt
$35,000,000
Employees

Team size

50+
Locations
HQ
Headquarters
$26,500,000 Post-IPO equity
GlobeNewswire News Room

Alimera Sciences Announces Exercise of Underwriters’ Over-Allotment Option and Closing of $26.5 Million Offering of Common Stock